PureTech Health PLC (PRTC): Price and Financial Metrics


PureTech Health PLC (PRTC): $32.51

1.55 (+5.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRTC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PRTC is 0.03 -- better than merely 10.1% of US stocks.
  • PRTC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 55.4, PURETECH HEALTH PLC has a higher such ratio than 96.55% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PURETECH HEALTH PLC are GLYC, AGLE, CRBU, VSTM, and BLDP.
  • PRTC's SEC filings can be seen here. And to visit PURETECH HEALTH PLC's official web site, go to www.puretechhealth.com.

PRTC Valuation Summary

  • PRTC's price/sales ratio is 55.4; this is 986.27% higher than that of the median Healthcare stock.
  • PRTC's price/earnings ratio has moved down 18.5 over the prior 26 months.

Below are key valuation metrics over time for PRTC.

Stock Date P/S P/B P/E EV/EBIT
PRTC 2023-01-20 55.4 1.6 -15.9 -9.7
PRTC 2023-01-19 58.3 1.7 -16.8 -10.6
PRTC 2023-01-18 55.2 1.6 -15.9 -9.6
PRTC 2023-01-17 48.9 1.4 -14.0 -7.7
PRTC 2023-01-13 48.8 1.4 -14.0 -7.7
PRTC 2023-01-12 48.8 1.4 -14.0 -7.7

PRTC Stock Price Chart Interactive Chart >

Price chart for PRTC

PRTC Price/Volume Stats

Current price $32.51 52-week high $43.57
Prev. close $33.47 52-week low $18.15
Day low $30.74 Volume 2,400
Day high $32.75 Avg. volume 1,633
50-day MA $30.23 Dividend yield N/A
200-day MA $26.98 Market Cap 905.63M

PureTech Health PLC (PRTC) Company Bio


PureTech Health PLC operates as a bio therapeutics company. The Company focuses on developing medicines for diseases based on insights into the biology and connectivity of the brain, immune, and gut systems. PureTech Health established the underlying programs and platforms that resulted in its broad pipeline of products and product candidates designed to treat diseases with unmet needs.


PRTC Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTC Latest Social Stream


Loading social stream, please wait...

View Full PRTC Social Stream

Latest PRTC News From Around the Web

Below are the latest news stories about PURETECH HEALTH PLC that investors may wish to consider to help them evaluate PRTC as an investment opportunity.

PureTech Provides End of Year Report on Key Progress

BOSTON, December 22, 2022--PureTech Provides End of Year Report on Key Progress

Yahoo | December 22, 2022

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

BOSTON, December 19, 2022--PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Yahoo | December 19, 2022

10 Best Immunology Stocks to Invest In

In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the […]

Yahoo | December 13, 2022

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

BOSTON, December 13, 2022--PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

Yahoo | December 13, 2022

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

BOSTON, December 12, 2022--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today shared new data supporting the clinical potential of LYT-200, a fully human monoclonal antibody (mAb) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia. The data were shared in a scientific poster presented at the American Soci

Yahoo | December 12, 2022

Read More 'PRTC' Stories Here

PRTC Price Returns

1-mo N/A
3-mo 6.98%
6-mo 26.10%
1-year -13.31%
3-year N/A
5-year N/A
YTD 1.91%
2022 -13.78%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5769 seconds.